Batu Chooses Unusual Path, Unusual Weapon

Crowdfunding Part of Financial Strategy; Cancer Fight Aims to Cut Tumors’ Blood Supply

When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… the company has filed 29 patents, raised over $2 million, and is gearing up to start testing its anti-cancer vaccine in humans.

Download full article here

Continue →
0

Startup applies to test cancer therapy

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.

The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the U.S. Food and Drug Administration approves the application.

ValloVax™ targets proteins found in blood vessels induced by cancer that are not present in ordinary ...

Continue →
0

Bringing Innovative Weapons To the Cancer Battlefront

What if we could engineer “killer cells” to wage war on tumors, and then program the little soldiers to seek a specific kill zone? What if glowing tumors could tell doctors which tissue material to remove during surgery?

These are just two of the recent breakthroughs in cancer research being undertaken by the hundreds of local bio- tech firms that are pumping money and resources into the oncology market — a market that’s booming with players, ...

Continue →
0

Startup Conducts Unusual Funding ‘Experiment’

A local biotech startup and its 22 year old CEO — with support of local industry veterans — are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine.

“If we raise money at this point in the preclinical stages, the venture capitalists or investors are going to take a large portion of our shares,” President and CEO Samuel Wagner said. “If ...

Continue →
0

Awarded Exclusive License from UC San Diego

Batu Biologics Awarded Exclusive License from University of California San Diego for Drug That Stimulates Immune System to Kill Cancer
Biotech Start Up Expands its Oncology Immunotherapeutic Product Pipeline

Productive and beneficial relationships with cutting-edge pharmaceutical companies such as Batu Biologics help speed further development of promising new drugs to those most in need.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Names Chief Scientific Officer

Batu Biologics Names Business Development and R&D Expert as Chief Scientific Officer
International Biotech Market Expert Will Help Boost Company’s Business Strategy

Her impeccable clinical trials expertise, combined with stellar interpersonal skills and keen knowledge of international markets, will serve the company well in its quest to be the first to successfully launch an anti-angiogenic lung cancer vaccine on the market.

Read the full article at businesswire.com

Continue →
0

Achieves Goal in Successful Crowdfunding Campaign

Batu Biologics Achieves Goal in Successful Crowdfunding Campaign
Biotech Startup Aims for FDA Approval for Novel Anti-Angiogenic Cancer Vaccine

Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform.

Read the full article at businesswire.com

Continue →
0
Page 1 of 2 12